Merck & Co., Inc. MRK
146.73 USD 0.00 (+0.00%)
At closeNov 9, 2026, 9:17 AM EST
148.00 +1.27 +0.87%
Pre-market · Nov 9, 9:17 AM ET
Day range unavailable
85.80 52-week range 156.92
- YTD
- +39.40%
- 1 year
- +71.05%
News
benzinga.com Moderna Stuns Wall Street With Surprise Profit, Raises Outlook Moderna (MRNA) jumps as Q3 earnings swing to a surprise profit of $0.38/share on strong global vaccine sales and cost cuts.
benzinga.com Growth Lead Sectors In Friday Trading As Defensives Trail Seven sectors are higher and four are lower in Friday’s regular session, with growth sectors holding the top three positions. The leaders are separated rather than clustered, with no single gap…
zacks.com MRK's Keytruda & Gardasil Sales Rise in Q3: Can the Momentum Last? Merck's Keytruda and Gardasil sales rise in Q3, but inventory reversals, slowing demand and looming competition could challenge growth.
defenseworld.net Merck & Co., Inc. $MRK Shares Sold by Boston Trust Walden Corp Boston Trust Walden Corp cut its holdings in shares of Merck and Co., Inc. (NYSE: MRK) by 12.0% during the third quarter, according to its most recent filing with the Securities and Exchange…
defenseworld.net AIA Group Ltd Sells 55,326 Shares of Merck & Co., Inc. $MRK AIA Group Ltd cut its stake in shares of Merck and Co., Inc. (NYSE: MRK) by 12.3% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange…
defenseworld.net 6,400 Merck & Co., Inc. $MRK Shares Purchased by Aware Super Pty Ltd as trustee of Aware Super Aware Super Pty Ltd as trustee of Aware Super boosted its stake in Merck and Co., Inc. (NYSE: MRK) by 15.3% during the undefined quarter, according to its most recent Form 13F filing with the…
reuters.com Merck gets US FDA emergency use nod for treatment of screwworm in dogs Merck gets US FDA emergency use nod for treatment of screwworm in dogs
fool.com 3 Stocks That Did Well the Last Time the Fed Raised Rates Aggressively In 2022, the last time rates rose quickly, these stocks surged, a couple of them by more than 80%.
247wallst.com Moderna Climbs 5% Ahead of Earnings, Pfizer Eases Despite Raised Outlook, Merck Slides 2% Despite New Phase 3 Trial Three of the biggest names in pharma and vaccines are trading against their own headlines. Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock is at $231.
247wallst.com Merck's Pipeline Could Be Its Next Big Growth Driver. Its Latest Earnings Offer a Clue. Merck just posted its sixth straight earnings beat and its CEO is targeting $70 billion in mid-2030s revenue, yet the stock carries a looming patent cliff that could reshape everything.
247wallst.com Buy, Sell, or Hold? Tuesday’s Top Upgrades and Downgrades: AON, Bloom Energy, Chevron, Cloudflare, Marvell Technologies, Lumentum Holdings, Merck & Co., Roku, X-Energy, and More Tech stocks keep beating estimates and then selling off anyway, Apple just joined the club, and Wall Street analysts are busy reshuffling their ratings on everything from nuclear energy plays to…
benzinga.com Merck Initiates Its ENHANCE-3 Phase 3 Randomized Clinical Trial Evaluating OHTUVAYRE For The Prevention Of Chronic Obstructive Pulmonary Disease Phase 3 randomized clinical trial evaluating OHTUVAYRE (ensifentrine) for the prevention of chronic obstructive pulmonary disease (COPD) exacerbations in adult patients receiving standard of care…
businesswire.com Merck Initiates Phase 3 Study Evaluating Ohtuvayre® (ensifentrine) for the Prevention of COPD Exacerbations in Adult Patients Receiving Standard of Care With a History of Exacerbations RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MERCK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of ENHANCE-3 (NCT07874815), a Phase 3 randomized…
fool.com Here's Why I Think Every Investor Needs to Invest in These "Miracle" Drugs The market for GLP-1 drugs is forecast to explode. It may be understated still.
benzinga.com Cantor Fitzgerald Maintains Neutral on Merck & Co, Raises Price Target to $155 Cantor Fitzgerald analyst Carter Gould maintains Merck & Co (NYSE:MRK) with a Neutral and raises the price target from $145 to $155.- benzinga.com Merck To Present New Data Across Its HIV Treatment And Prevention Pipeline And Portfolio At HIV Drug Therapy Glasgow 2026 Presentations include data on daily and investigational once-weekly oral treatments and investigational once-monthly oral HIV pre-exposure prophylaxisNew data include Phase 3 subgroup analyses and…
businesswire.com Merck to Present New Data from Its Broad Oral HIV Portfolio and Pipeline at HIV Glasgow 2026 RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--New data include Phase 3 subgroup analyses and patient-reported outcomes of investigational once-weekly oral combination of ISL/LEN.
defenseworld.net Merck & Co., Inc. $MRK Shares Bought by International Assets Investment Management LLC International Assets Investment Management LLC raised its position in Merck and Co., Inc. (NYSE: MRK) by 37.8% in the third quarter, according to the company in its most recent Form 13F filing with…
benzinga.com Elon Musk Says Eli Lilly Has ‘Some Banger Drugs Coming Out’ After CEO Dave Ricks Bets Against Vinod Khosla's Big Biotech Skepticism Elon Musk praises Eli Lilly’s upcoming drug pipeline as CEO Dave Ricks responds to skepticism about innovation at big biotech companies.
benzinga.com JP Morgan Maintains Overweight on Merck & Co, Raises Price Target to $175 JP Morgan analyst Chris Schott maintains Merck & Co (NYSE:MRK) with a Overweight and raises the price target from $165 to $175.
benzinga.com Merck One of Top Large-Cap Biopharma Picks-Analyst Merck beats Q3 estimates on oncology strength and raised guidance, while Guggenheim eyes pipeline progress ahead of Keytruda patent loss.
benzinga.com RBC Capital Maintains Sector Perform on Merck & Co, Lowers Price Target to $140 RBC Capital analyst Trung Huynh maintains Merck & Co (NYSE:MRK) with a Sector Perform and lowers the price target from $145 to $140.
benzinga.com Defensives Lead Sectors In Friday Trading As Growth Trails Five sectors are higher and six are lower in Friday's regular session, with defensive sectors holding the top three positions. The leaders are clustered rather than separated, while Technology sits…
benzinga.com Guggenheim Maintains Buy on Merck & Co, Raises Price Target to $171 Guggenheim analyst Vamil Divan maintains Merck & Co (NYSE:MRK) with a Buy and raises the price target from $170 to $171.
benzinga.com Merck's Keytruda Franchise Expands, Signals 'Modest' Revenue Growth in 2027 Merck beats Q3 estimates and raises 2026 guidance as Keytruda and Winrevair propel quarterly sales past Wall Street expectations.
benzinga.com Alphabet Sinks 11.8%, Small Caps Rally on Strong GDP Growth: Stock Market Today Alphabet's capex-heavy quarter drags the Nasdaq 100 lower while GDP beats and the Russell 2000 rallies, with three of four large caps rising.
benzinga.com 8 Of 11 Sectors Rise Thursday As Defensives Lead Eight sectors are higher and three are lower in Thursday’s regular session, with defensive sectors holding two of the top three positions. The leaders are separated rather than clustered, with Health…- benzinga.com Merck & Co Raises FY2026 Adj EPS Guidance from $2.66-$2.76 to $2.77-$2.82 vs $2.65 Est; Raises FY2026 Sales Guidance from $66.300B-$67.300B to $66.800B-$67.300B vs $67.052B Est Merck & Co (NYSE:MRK) raises FY2026 Adj EPS guidance from $2.66-$2.76 to $2.77-$2.82 vs $2.65 analyst estimate. Raises FY2026 sales outlook from $66.300 billion-$67.300 billion to $66.800…
benzinga.com Merck Q3 KEYTRUDA/KEYTRUDA QLEX Sales $8.60B (+6% Y/Y) Total Worldwide Sales Were $18.1 Billion (5% Growth; 4% Growth ex-FX)KEYTRUDA/KEYTRUDA QLEX1 Sales Were $8.6 Billion (6% Growth; 6% Growth ex-FX); Includes KEYTRUDA QLEX Sales of $830…
benzinga.com Merck & Co Q3 Adj. EPS $2.49 Beats $2.08 Estimate, Sales $18.085B Beat $17.313B Estimate Merck & Co (NYSE:MRK) reported quarterly earnings of $2.49 per share which beat the analyst consensus estimate of $2.08 by 19.71 percent. This is a 3.49 percent decrease over earnings of $2.58 per…
benzinga.com Stock Market: Will S&P 500 Open Up or Down Today? Will S&P 500 open higher? Polymarket odds dip to 47% as Wall Street weighs a tech selloff, Amazon earnings, PCE inflation, and cooling oil.
benzinga.com Traders Are Pricing a 7% Swing in Amazon Ahead of Earnings Amazon, Intel, Sandisk and six other stocks report earnings Thursday. See implied moves, analyst estimates and the billions in market value at stake.
benzinga.com Amazon, Eli Lilly On Deck Thursday As AWS Growth, Drug Demand Face Test Amazon headlines Thursday’s reports, with investors focused on whether accelerating AWS growth and heavy AI spending can support the next leg of its expansion. Eli Lilly, Mastercard, Merck,…
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Merck Endometrial Cancer Studies Show Significant Survival Gains Merck reports positive Phase 3 data for Keytruda and sac-TMT in endometrial cancer, showing significant survival gains at ESMO 2026.
benzinga.com Merck’s Phase 3 KEYNOTE-C93 Trial Meets Primary Endpoint Of Progression-Free Survival, Reducing Risk Of Progression Or Death By 43% With KEYTRUDA Monotherapy vs. Platinum Doublet Chemotherapy In dMMR Advanced Or Recurrent Endometrial Cancer KEYNOTE-C93 showed median progression-free survival (PFS) was more than four times longer for these patients treated with KEYTRUDA as monotherapy (38.2 months) compared to platinum doublet…
benzinga.com Merck Reports Phase 3 TroFuse-005 Trial Shows Sac-TMT Improves Overall And Progression-Free Survival, Meeting Both Dual Primary And Key Secondary Endpoints Of ORR In Advanced Or Recurrent Endometrial Cancer; FDA Priority Review Accepted TroFuse-005 is the first and only global Phase 3 study of a TROP2 ADC to demonstrate improved overall survival (OS) and progression-free survival (PFS) compared to chemotherapy in these patients who…- benzinga.com Barclays Maintains Overweight on Merck & Co, Raises Price Target to $180 Barclays analyst Emily Field maintains Merck & Co (NYSE:MRK) with a Overweight and raises the price target from $150 to $180.
benzinga.com BioNTech Evaluates Next Steps as Breast Cancer Drug Shows Limited Patient Benefit BioNTech and DualityBio report modest Phase 3 breast cancer survival gains alongside higher lung toxicity, limiting overall patient benefit.
benzinga.com Moderna Stock Saga: Leaked Data, a Panicked Influencer and Perfect Timing Moderna’s stock went on a wild ride last week that included a data leak and a dramatic tale from a social media influencer.
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Moderna Stock Slides Again Friday: What's Going On? Moderna slides in premarket trading post ESMO data leak, despite Phase 3 vaccine trial showing a 42% cut in melanoma recurrence.- benzinga.com Merck And Moderna Report Phase 3 Melanoma Trial Results For Personalized mRNA Cancer Therapy; Intismeran Plus KEYTRUDA Cuts Melanoma Recurrence Or Death Risk By 42% Intismeran plus KEYTRUDA significantly reduced the risk of recurrence or death by 42% (HR=0.58 [95% CI, 0.45–0.75]; two-sided p<0.001) compared to KEYTRUDA alone for patients with completely resected…
benzinga.com Why Is Moderna Stock Sinking Thursday? Moderna stock plummeted 25% following an alleged ESMO 2026 abstract leak showing lower-than-expected melanoma vaccine Phase 3 efficacy.
benzinga.com Defensives Lead Sectors In Thursday Trading As Growth Trails Five sectors are higher and six are lower in Thursday’s regular session, with defensive sectors holding the top three positions. The leaders are separated rather than clustered, with no single gap…- benzinga.com Merck Receives European Commission Approval For KEYTRUDA In Combination With Padcev For Adults With Resectable Muscle-Invasive Bladder Cancer European Commission (EC) has approved KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with Padcev® (enfortumab vedotin-ejfv), as neoadjuvant treatment and then continued after…
benzinga.com Energy Only Sector Lower In Tuesday Trading As Defensives Lead Ten sectors are higher and one is lower in Tuesday’s regular session, with defensive sectors holding two of the top three positions. The leaders are separated rather than clustered, with Health Care,…
benzinga.com Merck Discontinues Bacterial Infection Drug in Europe Merck withdraws bacterial infection drug Zinplava in the EU and after the December 2024 US market exit for commercial reasons.- benzinga.com European Commission Withdraws EU Marketing Authorisation For Zinplava At Merck Sharp & Dohme B.V.’s Request After Permanent Discontinuation For Commercial Reasons On 20 October 2026, the European Commission withdrew the marketing authorisation for Zinplava (bezlotoxumab) in the European Union (EU). The withdrawal was at the request of the marketing…
benzinga.com Novavax's Second-Largest Shareholder Sells $32.6 Million in Stock, Ends Activist Push Shah Capital sells 2.87M Novavax (NVAX) shares for $32.6M, ends activist campaign, and shifts to a family office structure.